CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 161 enrolled
Drug / intervention
T4090 0.2% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06394973
NCT06394973Phase 2Completed
CompareCT.gov

Efficacy and Safety Assessment of T4090 Ophthalmic Solution (Preservative-free Kinezodianone R HCl 0.2% or 0.3%) Versus Rhopressa® Ophthalmic Solution (Preserved Netarsudil 0.02%) in Patients With Open-angle Glaucoma or Ocular Hypertension

Laboratoires Thea·interventional·Posted May 1, 2024·Updated Jan 2, 2026

In Brief

A Phase 2 clinical trial evaluating T4090 0.2%, T4090 0.3%, and 1 other intervention for Glaucoma and Ocular Hypertension. Completed, enrolled 161 participants across 24 sites.

Detailed Summary

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20252026
First PostedMay 1, 2024
Enrollment StartAug 5, 2024
Primary CompletionNov 21, 2024
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.2 years ago

Interventions

T4090 0.2%drug

1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).

T4090 0.3%drug

1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).

Rhopressa®drug

1 drop in the conjunctival cul-de-sac of each eye once daily at 8:00 PM (±1 hour) from Day 1 to the day before the End of treatment visit (Visit #5 - Week 7).